You are an elite MBBS pharmacology professor, clinical pharmacologist, medical educator, pathophysiologist, and examination coach. Create a COMPLETE LEARNING NOTE for the topic(s) provided. The goal is NOT merely to summarize information. The goal is to teach the topic from absolute beginner level to MBBS examination mastery level. Assume the student has never seen the topic before. Write in extremely clear, plain English. Use language simple enough for a 9-year-old child to understand initially, then gradually build to MBBS level understanding. Never sacrifice understanding for brevity. Do not use unexplained jargon. Whenever a technical term is introduced: 1. Define it. 2. Explain why it matters. 3. Explain it using a simple analogy. 4. Explain it again in proper medical language. For every topic, use the following structure. --- SECTION 1: BIG PICTURE OVERVIEW Start with: "What problem does this drug class solve?" Explain: Why the disease occurs Why the microorganism survives What the drug is trying to achieve Where the drug acts Create a mental picture before discussing drugs. --- SECTION 2: BUILD THE FOUNDATION Before discussing drugs: Explain all background physiology. Explain all background microbiology. Explain all relevant pathology. Answer: What is normally happening? What goes wrong? Why does it go wrong? Where can drugs intervene? Use diagrams in text format where appropriate. Example: Bacterium ↓ Needs cell wall ↓ Cell wall keeps bacterium alive ↓ Drug blocks wall formation ↓ Wall becomes weak ↓ Bacterium dies --- SECTION 3: DRUG CLASS FRAMEWORK For each drug class explain: Definition Mechanism of action Why the mechanism works Spectrum of activity Important examples Clinical uses Adverse effects Contraindications Drug interactions Resistance mechanisms High-yield examination facts Common MCQs Most frequently tested concepts --- SECTION 4: TEACH USING ANALOGIES Create memorable analogies. Examples: Penicillin: "The bacterial cell wall is like a brick wall protecting a house. Penicillin prevents the workers from laying the bricks." Aminoglycosides: "The bacterial ribosome is like a factory producing products. Aminoglycosides force the factory to produce defective products." Sulfonamides: "Like cutting off a city's food supply." Always use vivid memorable analogies. --- SECTION 5: STEP-BY-STEP CLINICAL REASONING Teach how a doctor thinks. Example: Patient has pneumonia. Question 1: What organisms commonly cause it? Question 2: Which drugs cover those organisms? Question 3: Which drug reaches the lungs well? Question 4: What patient factors influence choice? Question 5: What adverse effects must be considered? Walk through reasoning systematically. --- SECTION 6: MEMORY TOOLS Create: Mnemonics Memory stories Visual memory tricks Drug comparison tables Rapid review boxes Focus only on useful mnemonics. --- SECTION 7: EXAMINER'S CORNER For each topic include: Most tested facts Most likely essay questions Most likely short notes Most likely viva questions Most likely MCQs Common traps students fall into How examiners phrase questions - SECTION 9: HIGH-YIELD REVISION SHEET End with: One-page revision summary Most important facts Must-know drugs Must-know toxicities Must-know mechanisms Must-know clinical uses Exam emergency facts --- SECTION 10: SELF-ASSESSMENT Create: 10 short-answer questions Provide answers with explanations. --- SPECIAL INSTRUCTIONS Do not assume prior knowledge. Teach before summarizing. Explain every mechanism step-by-step. Explain every adverse effect by linking it to physiology and pathophysiology. When discussing drugs, always answer: "What exactly is the drug doing?" "Why does that action help the patient?" "Why does that action produce the side effects?" "Why might resistance develop?" Use tables wherever helpful. Use comparison tables extensively. Make the note so comprehensive that an MBBS student can use it as their primary learning resource without needing another source for conceptual understanding. TOPICS TO COVER: Antiarrhythmics

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have all the information needed to write a comprehensive, exam-mastery level learning note. Let me compile it now:

ANTIARRHYTHMICS: COMPLETE LEARNING NOTE

From Absolute Beginner to MBBS Examination Mastery

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Katzung's Basic & Clinical Pharmacology 16e | Lippincott Illustrated Reviews: Pharmacology | Harrison's Principles of Internal Medicine 22e | Braunwald's Heart Disease | Goldman-Cecil Medicine | Washington Manual of Medical Therapeutics

SECTION 1: BIG PICTURE OVERVIEW

What Problem Do Antiarrhythmic Drugs Solve?

Imagine your heart as a perfectly coordinated drum band. Every drummer (cardiac cell) plays at exactly the right time, producing a beautiful rhythm. The conductor (the SA node - sinoatrial node) sets the beat for everyone else. Every cell waits for the conductor's signal, fires in perfect sequence, and your heart beats regularly, pumping blood to the body.

Now imagine what happens if one random drummer in the group starts beating on their own - too fast, too early, or completely out of sync. Or imagine a signal getting "trapped" in a loop, causing the drums to keep firing in circles. The whole rhythm falls apart. The heart either beats too fast, too slow, or in a completely chaotic, disorganized pattern.

That is what an arrhythmia is: a disorder of the normal electrical rhythm of the heart.

When the rhythm goes wrong:

The heart may beat too fast (tachyarrhythmia) and not fill with enough blood
The heart may beat too slow (bradyarrhythmia) and not pump enough blood
The ventricles may fibrillate (quiver uselessly) - this causes sudden cardiac death within minutes
Blood may pool and clot (especially in atrial fibrillation), causing strokes

Antiarrhythmic drugs restore normal rhythm by controlling the electrical behavior of cardiac cells.

They do this by targeting the ion channels (tiny gates in the cell membrane) that create the electrical signals, or by targeting the nervous system's control over the heart.

SECTION 2: BUILD THE FOUNDATION

2A. Normal Cardiac Electrophysiology - Start From Scratch

Step 1: What IS electricity in the heart?

Your heart cells are surrounded by a thin wall called the cell membrane. On one side of this membrane are positively charged particles (ions) like sodium (Na+), potassium (K+), and calcium (Ca2+). On the other side are different concentrations of the same particles.

Think of it like a battery: when positive charges are separated from each other by a membrane, there is a difference in electrical charge - this is called the membrane potential (measured in millivolts, mV).

At rest, the inside of a cardiac cell is approximately -85 to -90 mV compared to the outside. This means the inside is negatively charged. This is called the resting membrane potential.

How does it stay negative? Because:

A pump (Na+/K+-ATPase) actively pumps 3 Na+ OUT and only 2 K+ IN per cycle, creating a negative interior
K+ channels are open at rest, letting K+ slowly leak OUT, making the inside even more negative

This is the "battery being charged" - the cell is ready to fire.

Step 2: The Action Potential - The Electrical Signal

When a cardiac cell receives a stimulus (from the cell next to it), it fires an action potential - a brief, rapid change in membrane potential that travels like a wave through the heart.

This is exactly like falling dominoes: one tile falls (fires), which knocks over the next one, and the signal travels from the SA node all the way through the heart to make it contract.

The action potential has 5 phases, each controlled by different ion channels:

Cardiac Action Potential - Phases 0-4 showing ion movements

Figure: The cardiac action potential with each phase and the corresponding ion movements. This diagram is central to understanding ALL antiarrhythmic drug mechanisms. - Lippincott Illustrated Reviews: Pharmacology

Let's go through each phase carefully:

PHASE 0 - The Fast Upstroke (Rapid Depolarization)

What happens: Voltage-gated Na+ channels OPEN suddenly
Massive Na+ rushes INTO the cell (Na+ loves to enter because the inside is very negative and the concentration is much higher outside)
The inside of the cell shoots from -90 mV to +30 mV very rapidly
Analogy: Like a dam bursting - water (Na+) rushes through the flood gates

Why this matters for drugs: Class I antiarrhythmics block Na+ channels and slow down Phase 0. This slows the speed of signal conduction.

PHASE 1 - Brief Initial Repolarization

Na+ channels quickly INACTIVATE (close)
A transient K+ current flows briefly outward
The membrane voltage falls slightly from +30 mV back toward 0 mV

This phase is short and mostly relevant to Class IB drugs (like lidocaine) which shorten this phase.

PHASE 2 - The Plateau (The Most Unique Feature of Cardiac Cells)

Voltage-gated Ca2+ channels (L-type) OPEN and Ca2+ flows INTO the cell
This inward Ca2+ current is balanced by a slow outward K+ current
The voltage "plateaus" near 0 mV for 200-300 milliseconds
This Ca2+ is what triggers muscle contraction (excitation-contraction coupling)
The plateau also creates the refractory period - the heart cannot be stimulated again until Phase 2 is over

Why this matters: The plateau (Phase 2) creates the refractory period. No matter how many signals arrive, the heart cannot fire again until it fully repolarizes. This prevents the heart from having "tetanic" (sustained) contractions like skeletal muscle.

Class IV drugs (Ca2+ channel blockers) act mainly at the SA and AV nodes, which are more dependent on Ca2+ for their action potentials.

PHASE 3 - Rapid Repolarization

Ca2+ channels CLOSE
K+ channels OPEN widely, letting K+ rush OUT
The cell rapidly returns to negative resting potential (-85 to -90 mV)
This is restoration of the "charged battery"

Why this matters for drugs: Class III antiarrhythmics BLOCK K+ channels. This prevents K+ from rushing out, prolonging Phase 3. This makes the action potential duration (APD) and the refractory period longer, preventing rapid re-firing.

PHASE 4 - Resting Membrane Potential (or Spontaneous Depolarization in Pacemaker Cells)

In ordinary cardiac myocytes (working muscle cells): Phase 4 is flat - the cell just sits quietly at -90 mV waiting for the next signal
In pacemaker cells (SA node, AV node, His-Purkinje system): Phase 4 is NOT flat - there is a slow, spontaneous inward "funny current" (If) that gradually depolarizes the cell toward threshold
This is called automaticity - the ability to self-generate electrical signals

The SA node fires fastest (60-100 times per minute), so it is the dominant pacemaker. AV node fires at 40-60/min. Purkinje fibers fire at 20-40/min. These slower pacemakers are normally "overridden" by the SA node, but can take over if the SA node fails.

Why this matters: Class II drugs (beta-blockers) inhibit the sympathetic nerves that speed up Phase 4 depolarization in the SA and AV nodes. This is why beta-blockers slow the heart rate.

Key Difference: SA Node vs. Ventricular Muscle Cell Action Potential

The SA node (and AV node) are "slow response" cells that use Ca2+ channels predominantly (not Na+ channels) for their action potential upstroke. This is WHY:

Class IV drugs (Ca2+ channel blockers like verapamil, diltiazem) preferentially affect the SA and AV nodes
Class I drugs (Na+ channel blockers) mainly affect the atria, ventricles, and His-Purkinje system

SA NODE ACTION POTENTIAL:        VENTRICULAR ACTION POTENTIAL:
No fast upstroke                 Fast upstroke (Phase 0) - Na+
Slow Phase 4 depolarization      Flat Phase 4
Ca2+ driven                      Na+ driven initially, Ca2+ sustains plateau
Sensitive to Class II, IV        Sensitive to Class I, III

2B. The Cardiac Conduction System - The Electrical Highway

SA NODE (Right atrium)
    |
    | → Interatrial pathways → LEFT ATRIUM
    ↓
AV NODE (junction of atria and ventricles)
    ↓  [Important delay here - ~0.12 sec - allows ventricles to fill]
BUNDLE OF HIS
    ↓
RIGHT BUNDLE BRANCH → Right ventricle
LEFT BUNDLE BRANCH  → Left ventricle
    ↓
PURKINJE FIBERS (spread throughout ventricular walls)
    ↓
VENTRICULAR MYOCARDIUM contracts

Why the AV node delay matters: The 0.12-second pause at the AV node gives the atria time to finish contracting and push blood into the ventricles before the ventricles contract. This "top-up" is called the atrial kick. In atrial fibrillation, the atrial kick is lost.

Why this matters for drugs: Drugs that slow AV conduction (beta-blockers, Ca2+ channel blockers, digoxin, adenosine) are used to control ventricular rate in atrial arrhythmias, because they increase the AV nodal delay, meaning fewer atrial impulses reach the ventricles.

2C. How Arrhythmias Arise - The Two Main Mechanisms

Mechanism 1: Abnormal Automaticity

Normally, only the SA node fires spontaneously. But sometimes other cardiac cells develop the ability to fire on their own - this is called abnormal automaticity or ectopic automaticity.

Why does it happen?

Myocardial ischemia (low oxygen) damages cells, making them fire erratically
Hypokalemia (low K+) alters the resting membrane potential
Sympathetic overstimulation speeds up Phase 4 depolarization everywhere
Injury or stretching of cardiac tissue

Result: An ectopic pacemaker fires faster than the SA node and "takes over" the rhythm - like a rogue conductor grabbing the baton.

Analogy: Imagine a classroom where the teacher (SA node) normally sets the pace. If a student starts shouting instructions faster than the teacher, chaos ensues.

How drugs help: Class I and II drugs suppress abnormal automaticity by making Phase 4 depolarization slower or raising the threshold (the voltage the cell must reach before it can fire).

Mechanism 2: Re-entry (The Most Common Cause of Clinical Arrhythmias)

Re-entry is the single most important mechanism for clinical arrhythmias. It explains most SVTs, atrial flutter, atrial fibrillation, ventricular tachycardia, and WPW syndrome.

Reentry mechanism - normal conduction vs unidirectional block

Figure: Schematic of reentry. In normal conduction (A), the impulse travels down two pathways and terminates. In unidirectional block (B), the impulse is blocked in one direction but travels retrogradely through the other, re-entering the circuit and causing continuous circular excitation. - Lippincott Illustrated Reviews: Pharmacology

What is re-entry? Step-by-step:

Imagine a road system where an electrical impulse travels like a car:

Normally, the impulse travels down TWO parallel pathways (Path A and Path B)
Both paths meet at the bottom, the impulse collides with itself and dies out
Everything is normal. One beat. Over.

Now imagine Path A is blocked in one direction (unidirectional block) - perhaps due to ischemia:

The impulse travels down Path B normally
At the bottom, instead of dying, it turns backward through Path A (which allows backward travel, just not forward)
It travels back up Path A, exits, and re-enters the circuit at the top
It travels down Path B again...and again...and again
The circuit keeps going - circular re-excitation producing continuous arrhythmia

For re-entry to occur, three things must coexist:

Two pathways (anatomical or functional)
Unidirectional block in one pathway (the impulse can only go one way)
Slow conduction in the other pathway (so the first pathway has time to recover and allow retrograde conduction)

Conditions that cause re-entry:

Myocardial infarction (scar tissue creates slow conduction zones)
Hypertrophy
Accessory pathways (WPW - Wolff-Parkinson-White syndrome, where an extra electrical connection between atria and ventricles exists)
AV nodal re-entry (most common SVT)

How drugs terminate re-entry:

There are two approaches:

Slow conduction further (Class I Na+ channel blockers) - make the unidirectional block into a bidirectional block, so the impulse cannot travel in ANY direction through the damaged area. Circuit breaks.
Prolong the refractory period (Class III K+ channel blockers) - make cells stay refractory longer. When the circling impulse arrives, it finds the tissue still refractory (unable to respond). Circuit dies out.

Mechanism 3: Triggered Activity (Less Common but Important)

After a normal action potential, sometimes there are small "afterdepolarizations" - extra little bumps in voltage that can trigger another action potential.

Two types:

Early Afterdepolarizations (EADs): Occur during Phase 2 or Phase 3. Caused by prolonged action potential duration (e.g., from hypokalemia, drugs that prolong QT). EADs are responsible for Torsades de Pointes (TdP) - a dangerous ventricular tachycardia.
Delayed Afterdepolarizations (DADs): Occur after Phase 3, during Phase 4. Caused by intracellular Ca2+ overload (e.g., digitalis toxicity, catecholamine excess, heart failure). DADs are responsible for digitalis-induced arrhythmias.

2D. The ECG as a Window Into Electrical Activity

Every drug's effect on the ECG can be predicted from its mechanism:

PR INTERVAL:    Time for impulse to go SA node → AV node → ventricles
                Prolonged by: β-blockers, Ca²⁺ blockers, digoxin, adenosine
                (They slow AV nodal conduction)

QRS COMPLEX:    Time for ventricular depolarization (Phase 0 in ventricles)
                Widened by: Class I drugs (Na⁺ channel blockers slow Phase 0)

QT INTERVAL:    Total ventricular depolarization + repolarization time
                Prolonged by: Class IA drugs (prolong Phase 3 also)
                             Class III drugs (block K⁺ channels, prolong Phase 3)
                QT prolongation = RISK of Torsades de Pointes

High-yield ECG fact: QTc (corrected QT) > 500 ms = HIGH risk of Torsades de Pointes. The corrected QT is calculated using Bazett's formula: QTc = QT / √RR

SECTION 3: DRUG CLASS FRAMEWORK

The Vaughan-Williams Classification

The Vaughan-Williams classification (1970) is the most widely used system for categorizing antiarrhythmic drugs. It groups them by their predominant effect on the cardiac action potential.

CLASS I  →  Na⁺ channel blockers
   IA  →  Intermediate block, prolong APD
   IB  →  Fast on/off, shorten APD
   IC  →  Slow, marked conduction slowing

CLASS II →  Beta-adrenergic blockers (β-blockers)

CLASS III→  K⁺ channel blockers (prolong APD/refractory period)

CLASS IV →  Ca²⁺ channel blockers (non-dihydropyridine)

UNCLASSIFIED: Adenosine, Digoxin, Magnesium

Important limitation: Many drugs have actions in multiple classes. Amiodarone, for example, has Class I, II, III, and IV actions. Sotalol has Class II AND III actions. The Vaughan-Williams classification describes the predominant action, not the only one.

CLASS IA ANTIARRHYTHMICS

Quinidine, Procainamide, Disopyramide

Definition

Class IA agents are Na+ channel blockers with intermediate binding kinetics that also block K+ channels, producing intermediate slowing of Phase 0 AND prolongation of Phase 3.

Mechanism of Action - Detailed

Na+ channel blockade (Phase 0 effect):

Na+ channels exist in three states: Open (during Phase 0), Inactivated (during phases 1-3), and Resting/Closed (during Phase 4)
Class IA drugs bind to Na+ channels in their OPEN or INACTIVATED state
They have intermediate kinetics - they bind and unbind at a moderate rate (this is "use-dependent" block: the faster the heart beats, the more channels are blocked)
Blocking Na+ channels slows Phase 0 (the upstroke), which slows conduction velocity
ECG effect: WIDENED QRS complex

K+ channel blockade (Phase 3 effect):

Class IA drugs ALSO block some K+ channels (Ikr channels)
This slows K+ efflux, prolongs Phase 3 repolarization
The action potential duration (APD) and effective refractory period (ERP) are PROLONGED
ECG effect: PROLONGED QT interval

This combined Na+ and K+ blockade is the hallmark of Class IA - they affect both conduction AND repolarization.

The Three Class IA Drugs - Individual Profiles

QUINIDINE (the original, the prototype)

Mechanism: Na+ channel block + K+ channel block + anticholinergic + alpha-blocking effects

Clinical Uses:

Atrial fibrillation (AF) and atrial flutter - converting to sinus rhythm (largely replaced by newer drugs)
Wolff-Parkinson-White (WPW) syndrome - can block the accessory pathway
Historically: malaria treatment (quinidine is the dextro-rotatory isomer of quinine)

Adverse Effects (extremely high-yield - examiners love to test these):

Cinchonism: A syndrome caused by high quinidine levels. Symptoms: tinnitus (ringing in ears), headache, visual disturbances (blurred vision, photophobia), confusion, diarrhea. Named after the cinchona tree from which quinine (and quinidine) is derived.
Quinidine syncope: Paradoxically, quinidine can CAUSE arrhythmias (proarrhythmia). It prolongs the QT interval, which can trigger Torsades de Pointes (TdP) - a potentially fatal ventricular tachycardia. The patient suddenly loses consciousness (syncope).
Hypotension: Due to alpha-adrenergic blockade (vasodilation)
Diarrhea and GI upset: Very common, often the reason patients stop the drug
Thrombocytopenia and hemolytic anemia: Immune-mediated; rare
Drug interactions:
- Increases digoxin levels (VERY high-yield): Quinidine displaces digoxin from tissue-binding sites AND reduces digoxin's renal clearance. When starting quinidine in a patient on digoxin, the digoxin dose should be halved.
- Increases warfarin effects (inhibits CYP2C9): Increases bleeding risk
Anticholinergic effect (important): Quinidine also blocks muscarinic receptors. This can paradoxically SPEED UP AV nodal conduction (because normally the vagus nerve slows the AV node, and quinidine blocks this). In a patient with atrial flutter, this can dangerously accelerate the ventricular rate.

Contraindications: Pre-existing QT prolongation, heart failure (negative inotrope), severe conduction disease

PROCAINAMIDE

Mechanism: Na+ channel block. Its active metabolite, N-acetylprocainamide (NAPA), predominantly blocks K+ channels (Class III action).

Clinical Uses:

WPW syndrome with AF - drug of choice in many guidelines (blocks both normal and accessory conduction)
Acute ventricular tachycardia (IV form)
Atrial fibrillation
IV form useful in emergency settings

The Most Important Adverse Effect - Drug-Induced Lupus Erythematosus (DILE): This is the single most tested fact about procainamide.

With chronic use, procainamide causes a lupus-like syndrome in up to 25-30% of patients taking it long-term
The acetylator status determines risk: Slow acetylators metabolize procainamide slowly, accumulate the drug, and are MORE prone to lupus
Symptoms: arthralgia (joint pain), arthritis, pleuritis, pericarditis, skin rash
ANA (antinuclear antibody) becomes positive in nearly ALL patients on long-term therapy
Anti-histone antibodies are specifically associated (but the drug-induced form does NOT cause renal disease or CNS involvement unlike true SLE)
Reversible on stopping the drug - this distinguishes it from true SLE

Other adverse effects:

Agranulocytosis (decrease in white blood cells) - uncommon but dangerous
QT prolongation and TdP (like all Class IA)
Hypotension (IV administration)
GI side effects

DISOPYRAMIDE

Mechanism: Na+ channel block + K+ channel block + most potent anticholinergic effect of all Class IA drugs

Clinical Uses:

Atrial arrhythmias
Hypertrophic obstructive cardiomyopathy (HOCM): The negative inotropic effect is actually useful here - it reduces the outflow tract obstruction. Disopyramide + beta-blocker is a well-known combination for HOCM.

Adverse Effects:

Anticholinergic effects are predominant and the most tested:
- Urinary retention (especially in elderly men with BPH)
- Dry mouth
- Blurred vision
- Constipation
- Tachycardia
Negative inotrope - can precipitate heart failure (most potent negative inotrope among Class I drugs)
QT prolongation and TdP
Contraindicated in: Glaucoma, BPH (urinary retention risk), pre-existing heart failure

Mnemonic: DISOPYRAMIDE = Dry mouth, Increase urinary retention, Slow heart failure patients, Often avoided

CLASS IA Summary Table

Feature	Quinidine	Procainamide	Disopyramide
Na+ block	++	++	++
K+ block	++	+ (via NAPA)	++
Anticholinergic	+	+	+++ (strongest)
Alpha block	+ (hypotension)	-	-
Unique toxicity	Cinchonism, TdP, ↑digoxin	Drug-induced lupus (DILE)	Urinary retention, HF
Active metabolite	-	NAPA (Class III)	-
ECG effect	Wide QRS + Long QT	Wide QRS + Long QT	Wide QRS + Long QT

CLASS IB ANTIARRHYTHMICS

Lidocaine, Mexiletine, Phenytoin

Definition

Class IB agents are Na+ channel blockers with rapid on-off kinetics (fast dissociation from channels) that preferentially affect ischemic or depolarized tissue, and they shorten the action potential duration.

Mechanism of Action - Detailed

Na+ channel blockade with rapid kinetics:

Class IB drugs bind to Na+ channels in their OPEN or INACTIVATED state
Key difference from Class IA: They dissociate (come off) the channels very RAPIDLY
This means at normal heart rates, they barely affect healthy cells (the channels recover before the next beat)
BUT in ischemic tissue where cells are partially depolarized (resting near the threshold), channels are more often in the INACTIVATED state
Class IB drugs bind preferentially to INACTIVATED (partially depolarized) channels
This is called "use-dependent" or "state-dependent" block - they work best on fast or ischemic tissue

Shortening of APD (Phase 3 effect):

Unlike Class IA, Class IB drugs do NOT block K+ channels
In fact, they actually slightly ENHANCE K+ current, shortening Phase 3
This shortens the APD and effective refractory period
ECG effect: NARROW QRS, QT may actually shorten (minimal ECG change)

Why this makes them useful for ventricular arrhythmias (not atrial):

Ventricular cells have a longer APD than atrial cells
Class IB drugs preferentially shorten the ventricular APD
They also preferentially affect ischemic ventricular tissue (which is often the source of post-MI arrhythmias)
They have NO significant effect on the SA or AV node

LIDOCAINE (IV only)

The prototype Class IB drug. Also the prototype local anesthetic.

Mechanism: Na+ channel blocker with rapid kinetics, preferential effect on depolarized (ischemic) tissue

Routes of Administration: INTRAVENOUS ONLY for antiarrhythmic use. NOT effective orally due to massive first-pass metabolism in the liver.

Clinical Uses:

Acute ventricular arrhythmias - VT and VF post-MI (the classic indication)
Ventricular arrhythmias during cardiac surgery or catheterization
Digitalis-induced ventricular arrhythmias
NOT effective for atrial arrhythmias (this is high-yield)

Pharmacokinetics:

Half-life: about 2 hours
Metabolized extensively by liver (CYP enzymes)
In heart failure and liver disease, clearance is reduced - risk of toxicity
Must be given as IV loading dose followed by continuous infusion

Adverse Effects - Almost entirely CNS: The most testable fact: Lidocaine's toxicity is predominantly CNS (not cardiac). Progressive CNS toxicity with increasing levels:

Nystagmus - earliest sign (involuntary rapid eye movements)
Dizziness, drowsiness
Slurred speech, tinnitus
Seizures - the most serious CNS effect
Respiratory depression
At very high levels: cardiac depression

Memory trick: "Lid's side effects LID the brain" - Nystagmus, then drowsiness, then speech problems, then seizures.

Drug interactions:

Beta-blockers and cimetidine reduce lidocaine clearance → toxicity
Phenytoin may accelerate lidocaine metabolism

MEXILETINE (Oral analogue of lidocaine)

Mechanism: Same as lidocaine - oral Class IB Na+ channel blocker

Clinical Uses:

Oral suppression of ventricular arrhythmias (serves the same role as lidocaine but can be given by mouth)
Also used in channelopathies (sodium channel disorders causing long QT syndrome type 3)

Adverse Effects:

GI effects most common: Nausea, vomiting, dyspepsia, dysphagia (often taken with food)
CNS effects similar to lidocaine: tremor, dizziness, coordination problems
Narrow therapeutic index - need careful dosing
Metabolized by CYP2D6 (important drug interaction with CYP2D6 inhibitors)

PHENYTOIN (Dilantin)

Primarily an antiepileptic
Also a Class IB-like antiarrhythmic
Special use: Digitalis-induced arrhythmias (has been used historically)
The pharmacology student should recognize this overlap between antiepileptic and antiarrhythmic actions

Class IB Key Points

Feature	Lidocaine	Mexiletine
Route	IV only	Oral
Kinetics	Very fast on/off	Very fast on/off
Effect on APD	Shortens	Shortens
ECG effect	Minimal	Minimal
Main use	Acute VT/VF	Chronic ventricular arrhythmias
Main toxicity	CNS (seizures)	GI (nausea, vomiting)
Atrial arrhythmias	NOT effective	NOT effective

CLASS IC ANTIARRHYTHMICS

Flecainide, Propafenone

Definition

Class IC agents are the most potent Na+ channel blockers. They have slow dissociation kinetics (they stay on the channel for a long time) and cause marked slowing of conduction without significantly affecting the action potential duration.

Mechanism of Action - Detailed

Na+ channel blockade - maximum potency:

Class IC drugs bind Na+ channels very tightly (slow dissociation)
They profoundly slow Phase 0 upstroke
This markedly slows conduction velocity throughout the heart (especially in His-Purkinje and ventricular tissue)
ECG effect: Markedly WIDENED QRS (sometimes very wide)
They also slightly prolong the QT interval (due to QRS widening, not true K+ block)
They do NOT significantly affect the action potential duration or refractory period

Why are they so dangerous in structural heart disease?

This is the most critical clinical point about Class IC drugs, and it is heavily tested.

The CAST Trial (Cardiac Arrhythmia Suppression Trial, 1989) was a landmark trial that shook the antiarrhythmic drug world:

Patients after MI had frequent ventricular ectopic beats
It was thought (logically) that suppressing these ectopic beats with antiarrhythmics would reduce mortality
Flecainide and encainide (another Class IC drug) were used
Result: MORTALITY INCREASED in the treatment group compared to placebo
Flecainide and encainide INCREASED sudden cardiac death

Why? Because in ischemic/scarred tissue, marked conduction slowing by Class IC drugs creates NEW re-entry circuits and PROMOTES arrhythmias (proarrhythmic effect). The very drug intended to prevent arrhythmias was causing fatal ones.

The lesson from CAST: Class IC drugs are contraindicated in patients with structural heart disease (coronary artery disease, heart failure, left ventricular hypertrophy, prior MI).

FLECAINIDE

Clinical Uses:

Atrial fibrillation and atrial flutter in patients with NO structural heart disease (the "Pill-in-the-pocket" approach - patient takes flecainide only when AF starts)
Paroxysmal SVT
WPW syndrome (with caution)

Adverse Effects:

Proarrhythmia - most dangerous; CONTRAINDICATED in structural heart disease
Visual disturbances (blurred vision, halos)
Dizziness, headache
Negative inotrope - avoid in heart failure
Can convert AF to atrial flutter with very fast ventricular rate (flutter with 1:1 conduction - this is dangerous)

Contraindications: Structural heart disease (especially post-MI and heart failure), pre-existing bundle branch block

PROPAFENONE

Mechanism: Na+ channel block (Class IC) + weak beta-blocking activity + weak Ca2+ channel blocking activity

The beta-blocking activity makes it slightly different from pure flecainide
Can cause bronchospasm (due to beta-blockade) - avoid in asthma
Metabolized by CYP2D6 (poor metabolizers have more beta-blocking effect)

Clinical Uses: Same as flecainide - AF and SVT in structurally normal hearts

Adverse Effects:

Similar to flecainide
Additional: Bronchospasm (beta-blockade), metallic taste, liver toxicity, agranulocytosis (rare)
Increases digoxin and warfarin levels

Contraindications: Same as flecainide PLUS asthma/COPD (due to beta-blockade)

Class I Summary - The Big Picture

        Class IA          Class IB          Class IC
Phase 0     Slow              Slight slow       Marked slow
Phase 3     Prolonged         SHORTENED         Unchanged
APD         INCREASED         Decreased         Unchanged/slight increase
QRS         Widened           Minimal change    MARKEDLY widened
QT          Prolonged         Unchanged/shorter Slightly prolonged (from QRS widening)
Best for    Atrial + Ventricle Ventricle only   Atrial (NO structural disease)
Ischemic    Less selective    Preferential      Dangerous (proarrhythmia)
tissue

CLASS II ANTIARRHYTHMICS

Beta-Adrenergic Blockers (Beta-Blockers)

Definition

Class II antiarrhythmics are drugs that block beta-adrenergic receptors in the heart, reducing the influence of the sympathetic nervous system on cardiac automaticity and conduction.

Background Physiology

The sympathetic nervous system releases noradrenaline (norepinephrine) which binds to beta-1 receptors in the heart. This:

Increases heart rate (chronotropy) - speeds up Phase 4 depolarization in SA node
Increases AV nodal conduction speed (dromotropy) - shortens PR interval
Increases the slope of Phase 4 in all pacemaker cells
Increases contractility (inotropy)

Beta-blockers do the OPPOSITE:

Slow Phase 4 depolarization in SA node → decreased heart rate
Slow AV nodal conduction → prolonged PR interval, reduced ventricular rate

Mechanism of Action

Beta-blockers (propranolol, metoprolol, atenolol, esmolol) competitively block beta-1 receptors in the SA and AV nodes:

SA node: Phase 4 depolarization slope decreases → heart rate decreases (bradycardia)
AV node: Conduction velocity decreases → PR interval prolongs → fewer atrial impulses reach the ventricles

ECG effects: Bradycardia + prolonged PR interval

No significant effect on ventricular conduction or QRS width or QT interval (compared to Class I or III)

Clinical Uses (very high-yield)

Post-MI arrhythmia prevention - THE drug class of choice post-MI. Beta-blockers reduce sudden cardiac death after MI by 20-25%.
Rate control in atrial fibrillation and flutter - slow the ventricular response rate by blocking AV node
Supraventricular tachycardias (SVT) - especially AV nodal re-entrant tachycardia (AVNRT)
Sinus tachycardia due to sympathetic overactivity (thyrotoxicosis, anxiety, pheochromocytoma)
Ventricular arrhythmias due to sympathetic excess (exercise-induced VT, congenital long QT syndrome type 1)
Heart failure with reduced EF (carvedilol, metoprolol, bisoprolol) - reduce sudden death

Key Beta-Blocker Drugs in Antiarrhythmics

Drug	Selectivity	Half-life	Route	Special Feature
Propranolol	Non-selective (β1 + β2)	4-6 hours	Oral, IV	Prototype, lipophilic (CNS effects)
Metoprolol	Cardioselective (β1)	3-7 hours	Oral, IV	Preferred in asthmatics
Atenolol	Cardioselective (β1)	6-9 hours	Oral	Renal excretion
Esmolol	Cardioselective (β1)	9 MINUTES	IV only	Ultra-short acting, used in acute settings, perioperatively
Sotalol	Non-selective + K+ block	12 hours	Oral	Also Class III!
Carvedilol	β1 + β2 + α1 block	7-10 hours	Oral	Used in heart failure

Esmolol is particularly important to remember: its 9-minute half-life (metabolized by red blood cell esterases) makes it ideal for acute rate control - you can stop it quickly if needed.

Adverse Effects

Bradycardia - too slow heart rate
Heart block - can worsen pre-existing AV conduction disease
Bronchospasm - especially non-selective agents (block β2 in bronchial smooth muscle). CONTRAINDICATED in asthma and COPD (use cardioselective agents with caution)
Heart failure precipitation - negative inotropic effect (avoid in decompensated heart failure; but chronic use in stable HF is beneficial)
Cold extremities, Raynaud's - peripheral vasoconstriction
Masked hypoglycemia in diabetics - symptoms of hypoglycemia (tachycardia, tremor) are blocked; sweating is NOT masked (important distinction)
Fatigue, sleep disturbances, depression (especially with lipophilic agents like propranolol)
Impotence, sexual dysfunction
Lipid abnormalities - increased triglycerides, decreased HDL

Contraindications

Severe bradycardia or heart block (without pacemaker)
Decompensated heart failure
Asthma (non-selective agents absolutely contraindicated)
Cocaine toxicity (non-selective beta-blockers contraindicated - can cause unopposed alpha stimulation and severe hypertension/coronary vasospasm)
Pheochromocytoma (unless combined with alpha-blockade first)

CLASS III ANTIARRHYTHMICS

K+ Channel Blockers: Amiodarone, Sotalol, Dofetilide, Ibutilide, Dronedarone

Definition

Class III antiarrhythmics block K+ channels (predominantly Ikr - the rapidly activating delayed rectifier K+ current), prolonging Phase 3 repolarization and thus extending the action potential duration (APD) and effective refractory period (ERP).

Mechanism of Action

K+ channel blockade → K+ efflux slows → Phase 3 takes longer → APD and ERP prolonged → more time before the next impulse can come → anti-re-entry effect

ECG effect: Prolonged QT interval (QRS width is unchanged, but the ST segment and T wave are longer)

The prolonged ERP means:

In re-entry: the circling impulse arrives and finds tissue still refractory → circuit terminates
Rate of spontaneous firing decreases

The major risk: Prolonging Phase 3 too much → during the long repolarization, small inward currents can trigger an Early Afterdepolarization (EAD) → triggers Torsades de Pointes

AMIODARONE - "The Most Effective and Most Toxic Antiarrhythmic"

Amiodarone deserves its own extended section. It is unique because it has ALL FOUR classes of antiarrhythmic activity:

Action	Class	Clinical Significance
Na+ channel block	Class I	Slows conduction
Beta-blockade	Class II	Slows SA and AV node
K+ channel block	Class III	Prolongs APD, ERP - main antiarrhythmic effect
Ca2+ channel block	Class IV	Further slows SA, AV node

Additionally, amiodarone structurally resembles thyroid hormone and interferes with thyroid metabolism significantly.

Clinical Uses (extremely broad):

AF and atrial flutter - rate AND rhythm control
Ventricular tachycardia (VT) and ventricular fibrillation (VF) - the drug of choice for sustained VT/VF in patients with structural heart disease
Pulseless VT/VF in cardiac arrest - IV amiodarone (ACLS protocol)
Post-cardiac surgery arrhythmia prevention
AF in heart failure patients (amiodarone and dofetilide are the only antiarrhythmics shown not to increase mortality in heart failure)

Pharmacokinetics - Highly Unusual:

Extremely lipophilic - concentrates massively in fat, liver, lungs, skin, thyroid
Half-life: 40-55 DAYS (range 15-142 days) - the longest half-life of any drug in common use
Loading dose required (oral: typically 200-400 mg 3x/day for 1-2 weeks, then maintenance 100-400 mg/day)
Takes weeks to reach steady state; takes weeks to be eliminated after stopping
Low bioavailability (~40%) - variable absorption
Inhibits CYP2D6, CYP3A4, and P-glycoprotein → many drug interactions

Adverse Effects - Comprehensive (EXTREMELY HIGH YIELD):

The multiple toxicities of amiodarone are a favorite exam topic. Every organ system can be affected.

System	Adverse Effect	Details
Pulmonary	Pulmonary toxicity (pneumonitis/fibrosis)	1-15% of patients. Dry cough, dyspnea, pulmonary infiltrates on CXR, decreased DLCO. Can be fatal. Monitor CXR and PFTs every 12 months.
Thyroid	Both hypo- AND hyperthyroidism	2-5% per year. Amiodarone contains 37% iodine by weight. Hypothyroidism (more common in iodine-sufficient areas). Hyperthyroidism (more common in iodine-deficient areas). Monitor TSH every 6 months.
Eyes	Corneal microdeposits	Virtually 100% of patients on long-term therapy. Usually asymptomatic. Visible on slit lamp. Not a reason to stop drug unless causing visual symptoms. Rare optic neuritis can cause blindness.
Skin	Photosensitivity + blue-gray discoloration	Common. Blue-gray skin (especially sun-exposed areas) may not resolve on stopping drug.
Liver	Hepatotoxicity	Transaminase elevation common. Monitor ALT/AST every 6 months. Stop if >3x normal.
Neurological	Peripheral neuropathy, ataxia, tremor	Relatively common with long-term use
Cardiac	Bradycardia, heart block, QT prolongation	TdP is actually RARE despite QT prolongation (amiodarone prolongs APD uniformly, reducing TdP risk)
Thyroid	Note: amiodarone can INTERFERE with thyroid tests even without true dysfunction

The BLUE-GRAY skin and corneal deposits are among the most photographed exam questions. If you see a patient with chronic arrhythmia and blue-gray skin, think AMIODARONE.

Drug Interactions (critical):

Warfarin: Amiodarone inhibits CYP2C9 → increases warfarin levels dramatically → increase bleeding risk → reduce warfarin dose by 30-50% when starting amiodarone
Digoxin: Amiodarone increases digoxin levels by reducing its renal excretion and displacing it from tissue proteins → reduce digoxin dose by 50%
Many other interactions via CYP inhibition

Why does amiodarone cause less TdP than other Class III drugs despite QT prolongation?

Other Class III drugs cause heterogeneous QT prolongation (some areas of the heart repolarize later than others, creating dispersion of repolarization - the substrate for TdP)
Amiodarone causes homogeneous prolongation of repolarization throughout the heart, so dispersion is minimal
This is called "amiodarone paradox" - prolonged QT but low TdP risk

Monitoring Protocol for Amiodarone (high-yield for viva/clinicals):

Baseline: ECG, TFT (TSH), LFTs, CXR, PFTs, eye examination
Every 6 months: TFT, LFTs, clinical assessment for pulmonary symptoms
Every 12 months: CXR, PFTs
Eye exam if any visual symptoms

SOTALOL

Mechanism: Non-selective beta-blocker (Class II) + K+ channel block (Class III)

This dual mechanism makes sotalol unique: it slows the heart rate (like a beta-blocker) AND prolongs the refractory period (like Class III).

Clinical Uses:

AF and atrial flutter
Life-threatening ventricular tachycardia/fibrillation
Maintenance of sinus rhythm after cardioversion of AF

Adverse Effects:

Beta-blocker effects: Bradycardia, bronchospasm, fatigue (CONTRAINDICATED in asthma)
Class III effects: QT prolongation → TdP (more prone than amiodarone because it causes heterogeneous prolongation)
TdP risk is GREATER at SLOWER heart rates (reverse-use-dependent block - the channels are blocked more when the heart beats slowly, which is the opposite of use-dependent and is actually dangerous)

Important: Sotalol requires QTc monitoring. If QTc > 500 ms on treatment, stop the drug.

DOFETILIDE

Mechanism: Pure K+ channel blocker (specifically Ikr) - the most selective Class III drug

Clinical Uses:

AF and atrial flutter, especially in patients with heart failure (one of only two antiarrhythmics not shown to increase mortality in HF - the other being amiodarone)
Cardioversion of AF to sinus rhythm

Key Points:

Renally excreted - dose must be reduced in renal failure
Due to high TdP risk, dofetilide initiation requires in-hospital monitoring for at least 3 days with continuous QTc monitoring and dose adjustment
Patients are NOT discharged until dofetilide dose is stabilized and QTc is safe

IBUTILIDE

Mechanism: K+ channel block (Class III) + activates slow inward Na+ current → prolongs action potential

Clinical Uses:

IV only
Acute cardioversion of recent-onset AF and atrial flutter to sinus rhythm
Most effective for flutter (conversion rate ~60-70%)

Critical adverse effect: HIGH risk of TdP (up to 4% of patients). After IV ibutilide, patients MUST be monitored for at least 4 hours.

DRONEDARONE

Mechanism: Similar to amiodarone - has Class I, II, III, IV properties. But it does NOT contain iodine (amiodarone's iodine content is responsible for thyroid and some other toxicities).

Advantages over amiodarone: No thyroid toxicity, no pulmonary toxicity, no corneal deposits, shorter half-life (24 hours)

Disadvantages: Less effective than amiodarone; liver toxicity including severe hepatic failure requiring transplant has been reported

Critical contraindication: CONTRAINDICATED in permanent AF with heart failure - the PALLAS trial showed increased mortality when dronedarone was used in permanent AF with cardiovascular risk factors.

Clinical uses: Non-permanent AF in patients with normal LV function, as an alternative to amiodarone for maintaining sinus rhythm

Class III Summary Table

Drug	Mechanism	Route	Special Toxicity	Use
Amiodarone	Class I+II+III+IV	Oral, IV	Multi-organ (thyroid, lung, liver, skin, cornea)	Broadest - VT/VF, AF
Sotalol	Beta-block + K+ block	Oral	TdP, bronchospasm	AF, VT
Dofetilide	Pure K+ block	Oral	High TdP risk, renal dosing	AF (HF patients)
Ibutilide	K+ block + Na+	IV only	Very high TdP (4%)	Acute AF/flutter cardioversion
Dronedarone	I+II+III+IV (no iodine)	Oral	Hepatotoxicity; ↑ mortality in permanent AF with HF	Non-permanent AF

CLASS IV ANTIARRHYTHMICS

Non-Dihydropyridine Ca2+ Channel Blockers: Verapamil and Diltiazem

Definition

Class IV antiarrhythmics block L-type (long-lasting) voltage-gated Ca2+ channels in the heart, predominantly affecting the SA node and AV node.

Why ONLY the SA and AV Nodes?

Remember: the SA and AV nodes are "slow response" cells - they rely on Ca2+ channels (not Na+ channels) for their action potential upstroke.

Ventricular and atrial cells use fast Na+ channels predominantly.

So blocking Ca2+ channels has the most impact on SA and AV nodes.

Mechanism of Action

L-type Ca2+ channel block in SA and AV nodes:

SA node: Slows spontaneous Phase 4 depolarization AND slows Phase 0 upstroke → slower heart rate (negative chronotropy)
AV node: Slows Phase 0 of AV nodal cells → slower AV conduction → prolonged PR interval → fewer impulses get through to ventricles (rate control) → negative dromotropic effect
Myocardium: Reduced Ca2+ entry → reduced contractility (negative inotropic effect)

ECG effects: Bradycardia + prolonged PR interval (same as beta-blockers but mechanism is different)

Class IV Drugs: Verapamil vs. Diltiazem

Feature	Verapamil	Diltiazem
Type	Phenylalkylamine	Benzothiazepine
Heart effect	More negative inotrope	Less negative inotrope
Vasodilation	Less	More
Half-life	6-8 hours	3-4 hours (varies with formulation)
Routes	Oral, IV	Oral, IV
Use	SVT, rate control AF, HOCM	SVT, rate control AF, angina
Special toxicity	Constipation, gingival hyperplasia	Less constipation

Remember: Dihydropyridine Ca2+ channel blockers (nifedipine, amlodipine) are used for hypertension and angina. They act mainly on peripheral blood vessels. They have much less cardiac effect and are NOT antiarrhythmics.

Clinical Uses

Rate control in AF and atrial flutter (reduce ventricular rate)
Termination of AVNRT (paroxysmal SVT) - IV verapamil or diltiazem can terminate most SVTs within minutes by blocking the AV nodal component of the re-entry circuit
Stable angina (diltiazem)
HOCM (verapamil reduces outflow obstruction)

Adverse Effects

Bradycardia and AV block - most important cardiac effect
Negative inotropic effect - avoid in systolic heart failure (verapamil especially dangerous)
Hypotension
Constipation - verapamil is famous for this; sometimes used to treat diarrhea
Peripheral edema (especially with diltiazem)
Gingival hyperplasia - verapamil (like cyclosporine and nifedipine)
Gynecomastia - verapamil (rarely)

Critical Drug Interaction: Verapamil + Beta-Blockers = DANGEROUS

Verapamil and beta-blockers both slow the SA and AV nodes. Combining them can cause:

Severe bradycardia
Complete AV block
Asystole (cardiac standstill)

They should never be given together IV (can be used together orally with caution, but monitoring required).

Another critical interaction: Verapamil + Digoxin → verapamil increases digoxin levels → digoxin toxicity

Critical Contraindication: Verapamil is CONTRAINDICATED in WPW + AF

This is a classic exam trap:

In WPW syndrome, there is an accessory pathway (e.g., Bundle of Kent) between atria and ventricles. When AF occurs in WPW:

Normally, the AV node acts as a "gatekeeper" - it limits how fast impulses reach the ventricles
Verapamil/diltiazem slow the AV node further, BUT they can paradoxically SPEED UP conduction through the accessory pathway
This can lead to extremely rapid ventricular rates (300+ bpm) and ventricular fibrillation

In WPW with AF: Use procainamide or cardioversion. AVOID verapamil, diltiazem, beta-blockers, and digoxin.

UNCLASSIFIED ANTIARRHYTHMICS

ADENOSINE

Mechanism:

Adenosine binds to A1 receptors in the AV node
This activates a specific K+ channel (IKAch - acetylcholine-sensitive K+ channel)
K+ efflux hyperpolarizes the AV nodal cell → makes it harder to excite
Effectively causes a transient, complete AV block for about 10-30 seconds
Also inhibits cAMP generation → reduces Ca2+ entry

Clinical Uses:

DRUG OF CHOICE for acute termination of paroxysmal SVT (PSVT/AVNRT) - by transiently blocking the AV node, it interrupts the re-entry circuit and terminates the SVT
Diagnostic tool - helps distinguish SVT from VT (VT is not terminated by adenosine; SVT usually is)
Not effective for AF or flutter (they don't depend on AV nodal conduction for the arrhythmia itself)

Administration: Rapid IV bolus (6 mg first dose, then 12 mg if no response) followed immediately by rapid saline flush. Must be injected fast because adenosine has an extremely short half-life (< 10 seconds - metabolized by red blood cells and vascular endothelium). Must be given through a large, proximal vein.

Adverse Effects:

Flushing - very common, harmless
Chest tightness and dyspnea - brief bronchospasm; AVOID in asthma (use verapamil instead)
Transient sense of doom - patients often describe a brief, terrifying sensation of impending death (caused by the brief AV block)
Transient AV block, sinus pause - these are expected and brief

Key Facts:

Theophylline (and caffeine) are adenosine ANTAGONISTS - they block A1 receptors. A patient who just had coffee may need a higher dose of adenosine.
Dipyridamole (blocks adenosine reuptake) POTENTIATES adenosine - a smaller dose is needed.
Adenosine is safe in WPW (it only blocks AV node, not the accessory pathway) for diagnostic purposes.

DIGOXIN (Cardiac Glycoside)

Mechanism:

Primary mechanism: Inhibits Na+/K+-ATPase (the sodium pump)
Na+ accumulates inside the cell → Na+/Ca2+ exchanger works less → Ca2+ inside the cell increases
Higher intracellular Ca2+ → increased contractility (positive inotropic effect)
Indirect vagotonic effect (stimulates the vagus nerve) → slows SA node and AV node

Clinical Uses:

AF: Rate control (slows ventricular rate by increasing AV nodal block via vagus nerve)
Heart failure with reduced EF (positive inotropic effect - increases contractility; improves symptoms and reduces hospitalization, but does NOT reduce mortality)
Atrial flutter (rate control)

The Narrow Therapeutic Index - Critical:

Therapeutic range: 0.5-2.0 ng/mL
Toxic level: >2.0-2.5 ng/mL
Very easy to overdose

Factors that increase digoxin toxicity risk:

Hypokalemia (MOST IMPORTANT): K+ and digoxin compete for the Na+/K+-ATPase binding site. If K+ is low, more digoxin binds → enhanced effect/toxicity. This is why diuretic-induced hypokalemia is dangerous in patients on digoxin.
Hypomagnesemia
Hypercalcemia
Hypothyroidism
Renal failure (digoxin is renally excreted; dose must be reduced)
Old age (reduced renal clearance)
Drug interactions: Amiodarone, quinidine, verapamil all increase digoxin levels

Digoxin Toxicity - Signs and Symptoms:

GI: Anorexia, nausea, vomiting (earliest and most common)
CNS: Confusion, delirium, visual disturbances (classic: yellow-green vision - xanthopsia, or halos around lights - chromatopsia)
Cardiac: Almost ANY arrhythmia! But most characteristic: paroxysmal atrial tachycardia with AV block (PAT with block), ventricular bigeminy, AV block
In children: Sinus bradycardia is often the first sign

Treatment of Digoxin Toxicity:

Stop digoxin
Correct hypokalemia and hypomagnesemia
For bradycardia/AV block: Atropine or pacing
For ventricular arrhythmias: Lidocaine or phenytoin (NOT quinidine or Class IC - they can worsen)
For severe toxicity: Digoxin-specific antibody fragments (Digibind/DigiFab) - the antidote

MAGNESIUM SULFATE

Mechanism: Mechanism not fully elucidated; may stabilize membranes, affect ion channels

Clinical Uses:

Treatment of Torsades de Pointes - IV magnesium is the first-line treatment for TdP, even if serum Mg2+ is normal
Digoxin-induced arrhythmias
Hypomagnesemia-associated arrhythmias

SECTION 4: TEACH USING ANALOGIES

Analogies to Make This Stick Forever

The Orchestra Analogy

The heart is a perfectly coordinated orchestra. The SA node is the conductor. Every musician (cardiac cell) watches the conductor and plays in sequence. An arrhythmia is what happens when:

A random musician starts playing out of turn (abnormal automaticity)
A sound bounces between the walls and creates an echo that keeps repeating (re-entry)
A musician gets startled by a loud sound and plays an extra note (triggered activity)

Antiarrhythmic drugs are like the rules the concert hall enforces to prevent chaos.

Class I Drugs: The Door Analogy

Na+ channels are like swinging doors that let sodium rush into the cell. Class I drugs put a LOCK on the door - varying speed and strength:

Class IA: A padlock - moderately slows entry, AND makes the hallway longer (prolongs Phase 3). Think "moderate lock that also lengthens the corridor."
Class IB: A weak magnet - barely locks, AND actually shortens the hallway. Works best on "broken" (ischemic) doors.
Class IC: A DEADBOLT - slam! Door barely opens at all. Great in healthy corridors, CATASTROPHIC in damaged ones.

Class III Drugs: The Hotel Room Analogy

After a cardiac cell fires, it must "recover" (repolarize) before it can fire again - like a hotel room that must be cleaned before the next guest.

Class III drugs slow down the cleaning crew (block K+ channels) → the room takes longer to be ready → the next impulse has to WAIT → re-entry circuits break because they arrive to find the room still being cleaned.

Amiodarone is like a thorough cleaning company that also fixes pipes, replaces lightbulbs, checks the HVAC, and repaints - it does everything (Class I+II+III+IV) but it also damages the building over time (multi-organ toxicity).

The Reentry Circuit: Broken Ring Road

Imagine a ring road around a city. Normally, cars enter, go around, and exit. A unidirectional road block means cars can only go clockwise. Normally this would mean cars accumulate. But if a back road exists, some cars loop backwards on it - and now they keep driving in circles forever. Antiarrhythmic drugs either:

Block the back road more completely (Class I - bidirectional block)
Put up a "road closed for maintenance" sign for longer (Class III - prolong refractory period so cars arrive and find the road closed)

Amiodarone: The Good Chemotherapy

Like chemotherapy, amiodarone is the most effective option for the worst arrhythmias, but it comes at a price - multi-organ toxicity with long-term use. You use it when you need it most, monitor carefully, and use the minimum effective dose.

Lidocaine: The Firefighter Who Only Works Where There's Fire

Lidocaine preferentially acts on ischemic (depolarized) tissue - exactly where the fire (arrhythmia source) is. It barely touches healthy tissue. This targeted action is why it is so useful for post-MI arrhythmias.

Digoxin: The Strong-Willed Helper With a Temper

Digoxin strengthens the heart (positive inotropic effect) and slows the rate, but it has a "temper" - the therapeutic index is so narrow that it can easily cause the very arrhythmias it is meant to prevent. And low potassium makes it even more volatile.

SECTION 5: STEP-BY-STEP CLINICAL REASONING

Case 1: Patient with Atrial Fibrillation

Patient: 65-year-old man with hypertension and palpitations. ECG shows irregularly irregular rhythm, no P waves - confirmed AF.

Step 1: What are the GOALS of treatment in AF?

Rate control (slow the ventricular rate to < 110 bpm at rest)
Rhythm control (restore and maintain sinus rhythm)
Anticoagulation (prevent stroke)

Step 2: Rate control - Which drug?

For most patients: Beta-blocker (metoprolol) or non-dihydropyridine Ca2+ channel blocker (diltiazem, verapamil)
In heart failure with reduced EF: Beta-blocker or digoxin (Ca2+ channel blockers with negative inotropy are dangerous here)
In COPD/asthma: Diltiazem or verapamil (not beta-blockers)
Rapid effect needed? IV metoprolol or IV diltiazem

Step 3: Rhythm control - Which drug?

No structural heart disease: Flecainide or propafenone (Class IC) - well-tolerated "pill-in-pocket" option
Structural heart disease (HF, LVH, CAD): Amiodarone (safe, effective) OR dofetilide (in HF)
Post-MI (structural heart disease): NEVER use Class IC (CAST trial!)

Step 4: Can we cardiovert?

AF < 48 hours: Can cardiovert without prolonged anticoagulation
AF > 48 hours: Anticoagulate for 3 weeks before cardioversion (or do TEE to rule out atrial thrombus)
Pre-cardioversion antiarrhythmic loading to maintain sinus rhythm: Amiodarone, propafenone, or flecainide

Summary of AF drug choice:

AF Patient
   ├── Rate control:
   │     ├── Normal LV function → β-blocker or Ca²⁺ blocker
   │     └── HF → β-blocker or digoxin
   └── Rhythm control:
         ├── No structural disease → Flecainide/Propafenone/Sotalol/Dronedarone
         └── Structural disease (HF, CAD, LVH) → AMIODARONE or Dofetilide

Case 2: Narrow Complex Tachycardia (SVT/AVNRT) in Emergency

Patient: 30-year-old woman with sudden palpitations, HR 190 bpm, narrow QRS on ECG.

Step 1: Try vagal maneuvers first

Valsalva maneuver (bear down), carotid sinus massage
Increases vagal tone → slows AV node → may terminate SVT

Step 2: If vagal maneuvers fail → Adenosine

Give 6 mg rapid IV bolus (followed by fast saline flush) into a large antecubital vein
This blocks AV node for 10-30 seconds
In AVNRT (most common SVT): This terminates the re-entry circuit through the AV node
Success rate ~90%

Step 3: If adenosine fails

Give 12 mg adenosine (repeat once)
Or switch to IV verapamil or IV diltiazem

Step 4: If patient is hemodynamically unstable (hypotension, chest pain, collapse)

SKIP medications
Immediate synchronized DC cardioversion

Step 5: Prevention of recurrent SVT

Catheter ablation (definitive cure for AVNRT)
Long-term: Verapamil, diltiazem, or beta-blockers

Case 3: Post-MI Patient With Frequent PVCs

Patient: 55-year-old man, 3 days post-MI, multiple PVCs on telemetry.

Step 1: Are these PVCs dangerous?

PVCs post-MI can degenerate into VT/VF - they represent the substrate for re-entry in ischemic tissue

Step 2: Drug choice?

Beta-blocker (metoprolol) - FIRST LINE. Reduces mortality post-MI, prevents VT/VF
NOT Class IC drugs (CAST trial - increases mortality)
NOT quinidine (no mortality benefit, proarrhythmic)
For established VT: IV lidocaine or amiodarone

Step 3: If the patient develops sustained VT or VF?

Unstable → IMMEDIATE defibrillation
Pulseless VT/VF → CPR + defibrillation + IV amiodarone (300 mg) or IV lidocaine

Case 4: Torsades de Pointes

Patient: Woman on QT-prolonging antibiotics (azithromycin) + sotalol. QTc 540 ms. Develops polymorphic VT that self-terminates repeatedly.

Step 1: Recognize TdP

QT prolongation + polymorphic VT with characteristic "twisting of points" pattern on ECG

Step 2: Immediate treatment

IV MAGNESIUM SULFATE (2 g bolus) - first-line even if Mg2+ is normal
Remove the offending drug (stop sotalol, stop azithromycin)
Correct electrolytes (correct hypokalemia, hypomagnesemia)

Step 3: If TdP persists

Increase heart rate: Atropine (IV) or temporary pacing at 90-110 bpm (faster rate shortens QT interval and prevents TdP)
Isoproterenol infusion (increases rate, shortens QT)

Step 4: Prevention

Avoid QT-prolonging drugs
Correct electrolytes before using antiarrhythmics
Genetic testing for congenital long QT syndrome

SECTION 6: MEMORY TOOLS

Mnemonic 1: Class IA Drugs - "Queen PD Has Anticholinergic Effects"

Quinidine, Procainamide, Disopyramide

Quinidine: Cinchonism, Digoxin interaction (↑levels)
Procainamide: Lupus (drug-induced), Slow acetylators more prone
Disopyramide: Urinary retention (anticholinergic), Heart failure risk

Mnemonic 2: Procainamide = SLENA

Slow acetylators more prone to lupus
Lupus-like syndrome (SLE) - unique toxicity
Extended active metabolite: NAPA (Class III)
NAPA is the active metabolite
Agranulocytosis (rare but serious)

Mnemonic 3: Class IB "Ischemic heart's BFF" - Lidocaine and Mexiletine

Works best on ischemic (depolarized, inactivated) tissue
Brain toxicity for lidocaine (NOT heart)
Fast kinetics
First choice post-MI acute VT

Mnemonic 4: Class IC - "CAST ME OUT of ischemic hearts"

CAST trial showed they INCREASE mortality in structural heart disease
Marked QRS widening
Exclude from any structural heart disease patient
Use only in pristine (structurally normal) hearts for AF

Mnemonic 5: Amiodarone Side Effects - "THYROID PLATE"

Thyroid (hypo AND hyperthyroidism)
Hepatotoxicity
Yellow/Blue: corneal deposits + blue-gray skin
Respiratory: pulmonary toxicity/fibrosis
Ophthalmologic: optic neuritis, corneal deposits
Interacts: warfarin (↑), digoxin (↑)
Depolarization: slows SA, AV nodes
Photosensitivity
Long half-life (40-55 days)
All four Vaughan-Williams class actions
The best antiarrhythmic (most effective)
Every organ can be affected

Mnemonic 6: Class III K+ blockers - "SAD DI"

Sotalol (also beta-blocker)
Amiodarone
Dofetilide
Dronedarone
Ibutilide (IV only, acute AF)

Mnemonic 7: Drugs That Prolong QT (Risk of TdP) - "MACHO QT"

Macrolide antibiotics (azithromycin)
Antiarrhythmics Class IA and III
Cisapride (prokinetic - withdrawn in many countries)
Haloperidol and antipsychotics
Other: fluoroquinolones, tricyclics, antihistamines (terfenadine - withdrawn)
Quinidine specifically (Class IA)
Triggered by hypokalemia, hypomagnesemia, bradycardia

Mnemonic 8: Digoxin Toxicity Signs - "NAVY GI"

Nausea/Vomiting (GI - first sign)
Arrhythmias (any type; PAT with block is classic)
Vision changes (yellow-green xanthopsia, halos)
Yellow-green vision (xanthopsia)
GI upset
Inhibited Na/K-ATPase by digoxin

Drug Comparison Table: The Big Picture

Drug Class	Na+	K+	Ca2+	β-block	APD	QRS	QT	Best Use	Worst Danger
IA (Quinidine)	++	++	-	-	↑	Wide	↑	AF/VT	TdP, cinchonism
IA (Procainamide)	++	+	-	-	↑	Wide	↑	WPW+AF, VT	Drug-induced lupus
IA (Disopyramide)	++	++	-	-	↑	Wide	↑	AF, HOCM	Urinary retention, HF
IB (Lidocaine)	++	-	-	-	↓	Min	↓	Acute VT/VF post-MI	CNS toxicity (seizures)
IB (Mexiletine)	++	-	-	-	↓	Min	↓	Chronic VT	Nausea/vomiting
IC (Flecainide)	+++	-	-	-	~=	Wide↑↑	~=	AF (no struct. disease)	Proarrhythmia, ↑ mortality in MI
II (Metoprolol)	-	-	-	++	~=	~=	~=	Post-MI, AF rate, SVT	Bronchospasm, bradycardia
III (Amiodarone)	++	+++	++	++	↑↑	~=	↑	VT/VF, AF, HF+AF	Multi-organ toxicity
III (Sotalol)	-	+++	-	++	↑	~=	↑	AF, VT	TdP, bronchospasm
III (Dofetilide)	-	+++	-	-	↑	~=	↑	AF in HF	TdP, renal dosing
IV (Verapamil)	-	-	++	-	~=	~=	~=	SVT, AF rate	HF, bradycardia, constipation
Adenosine	-	-	-	-	~=	~=	~=	Acute SVT	Flushing, bronchospasm
Digoxin	-	-	-	~=	-	~=	~=	AF rate, HF	Narrow TI, hypokalemia TDI

Quick Visual: Where Each Class Acts on the Action Potential

+30 mV ─────────────────╮
                    Phase 1\                Phase 2 (Plateau)
                            ─────────────────────╮
0 mV                                              \
                                                   \─── Phase 3
-90 mV ────────────────────────────────────────────────────────
                     Phase 4 (flat in ventricle / slopes in SA node)

CLASS IA  = Slows Phase 0 upstroke + Prolongs Phase 3
CLASS IB  = Slightly slows Phase 0 + Shortens Phase 3
CLASS IC  = Markedly slows Phase 0 (minimal Phase 3 effect)
CLASS II  = Decreases Phase 4 slope (SA/AV node)
CLASS III = Prolongs Phase 3 (K+ channel block)
CLASS IV  = Slows Phase 0 of SA/AV node (Ca2+ dependent)

SECTION 7: EXAMINER'S CORNER

Most Likely Essay Questions (MBBS Final Exams)

"Classify antiarrhythmic drugs. Describe the mechanism of action, clinical uses, and adverse effects of amiodarone."
- Answer structure: Vaughan-Williams classification (table) → amiodarone: Class I+II+III+IV mechanism → uses (VT, VF, AF, AF in HF) → toxicities (thyroid, pulmonary, hepatic, skin, corneal, neurological) → monitoring
"Describe the pharmacological basis and management of atrial fibrillation."
- Answer structure: Background on AF (re-entry, AV node) → rate control drugs (beta-blockers, Ca2+ blockers, digoxin) → rhythm control (flecainide/propafenone in structurally normal heart; amiodarone in structural disease) → CAST trial → anticoagulation
"Write short notes on: (a) Drug-induced lupus, (b) Torsades de Pointes, (c) Lidocaine toxicity."
"Describe the mechanism of action and clinical uses of adenosine as an antiarrhythmic drug."
"What are the mechanisms by which cardiac arrhythmias arise? How do antiarrhythmic drugs act to suppress them?"

Most Likely Short Notes

Amiodarone - mechanism and toxicity
Lidocaine as antiarrhythmic
Drug-induced lupus (procainamide)
Digoxin toxicity and treatment
Torsades de Pointes
CAST trial and its significance
Adenosine in SVT
Class III antiarrhythmics
QT prolongation by drugs
Verapamil vs. diltiazem

Most Likely Viva Questions

"What is the mechanism of action of lidocaine? Why is it not given orally?"
- Na+ channel block; IV only because of massive first-pass metabolism in liver; first-pass hepatic extraction ~70%
"Why is flecainide contraindicated after myocardial infarction?"
- CAST trial showed increased mortality; in ischemic tissue, Class IC drugs create NEW re-entry circuits and cause proarrhythmia
"What is the most serious adverse effect of procainamide? Who is more prone?"
- Drug-induced lupus (DILE); slow acetylators are more prone
"How does amiodarone cause thyroid toxicity?"
- Contains 37% iodine by weight; chronic iodine load; also structurally resembles T4 and inhibits thyroid hormone binding/conversion. Both hypo- and hyperthyroidism possible.
"What is the antidote for digoxin toxicity?"
- Digoxin-specific antibody fragments (Fab fragments) - Digibind/DigiFab
"Why is verapamil contraindicated in WPW with AF?"
- WPW has accessory pathway bypassing AV node. Verapamil blocks AV node but can accelerate conduction through the accessory pathway → very rapid ventricular rate → VF.
"What is the mechanism of quinidine syncope?"
- QT prolongation → Torsades de Pointes → loss of consciousness (syncope)
"Which drug is used for Torsades de Pointes?"
- IV Magnesium Sulfate (2g bolus) is first-line
"What are the ECG effects of Class I antiarrhythmics?"
- Class IA: Widened QRS + prolonged QT
- Class IB: Minimal ECG change (may shorten QT)
- Class IC: Markedly widened QRS
"Why does amiodarone rarely cause TdP despite prolonging the QT interval?"
- Amiodarone prolongs APD homogeneously (uniformly) throughout the myocardium → minimal dispersion of repolarization → low TdP risk. Other Class III drugs cause heterogeneous prolongation → high TdP risk.

Most Likely MCQs with Traps

MCQ 1: A patient on digoxin is started on quinidine. What adjustment must be made?

A) Increase digoxin dose
B) Reduce digoxin dose by half ← CORRECT
C) Stop digoxin
D) No change needed
Trap: Students forget that quinidine both displaces digoxin from tissue proteins AND reduces its renal clearance, doubling blood levels.

MCQ 2: Which antiarrhythmic should be AVOIDED in asthma?

A) Verapamil
B) Adenosine
C) Sotalol ← CORRECT (also D is true but between them sotalol is most specifically contraindicated as antiarrhythmic)
D) Propafenone
Explanation: Sotalol has both beta-blocking and K+ channel blocking actions; its beta-blockade causes bronchospasm. Adenosine also causes bronchospasm; propafenone also has weak beta-blocking effects. In a strict MCQ context, sotalol and propafenone are specifically contra-indicated in asthma. Verapamil is preferred for SVT in asthmatic patients.

MCQ 3: A 55-year-old post-MI patient has frequent PVCs. Which drug is CONTRAINDICATED?

A) Metoprolol
B) Amiodarone
C) Flecainide ← CORRECT
D) Lidocaine
Trap: CAST trial - Class IC drugs (flecainide, encainide) increase mortality in post-MI structural heart disease.

MCQ 4: What is the first sign of lidocaine toxicity?

A) Nystagmus ← CORRECT
B) Seizures
C) Cardiac arrest
D) Hypotension
Trap: Students jump to seizures (the most dramatic toxicity), but nystagmus is the EARLIEST sign.

MCQ 5: Which drug causes a lupus-like syndrome as an adverse effect?

A) Quinidine
B) Disopyramide
C) Procainamide ← CORRECT
D) Lidocaine

MCQ 6: Adenosine's mechanism in terminating SVT involves:

A) Na+ channel blockade
B) Activation of K+ channels via A1 receptors (IKAch) ← CORRECT
C) Beta-adrenergic blockade
D) Ca2+ channel blockade

MCQ 7: Quinidine's ability to cause QT prolongation is due to blockade of:

A) Na+ channels
B) K+ channels (Ikr) ← CORRECT
C) Ca2+ channels
D) Beta receptors

MCQ 8: Disopyramide is useful in which of the following conditions (besides arrhythmias)?

A) Heart failure
B) BPH
C) Hypertrophic Obstructive Cardiomyopathy (HOCM) ← CORRECT
D) Asthma
Trap: Disopyramide is negative inotropic which is HARMFUL in heart failure but USEFUL in HOCM (reduces outflow obstruction).

MCQ 9: The drug of choice for terminating Torsades de Pointes is:

A) Lidocaine
B) IV Magnesium Sulfate ← CORRECT
C) Amiodarone
D) Quinidine
Trap: Students choose amiodarone (the "powerful" antiarrhythmic), but TdP requires magnesium first. Note: DO NOT use Class IA or Class III drugs (they prolong QT further!).

MCQ 10: Which of the following antiarrhythmics is safe to use in patients with atrial fibrillation AND heart failure with reduced ejection fraction?

A) Flecainide
B) Dronedarone
C) Amiodarone ← CORRECT (also dofetilide, but amiodarone is more commonly tested)
D) Propafenone

Common Student Traps in Examinations

Saying amiodarone causes TdP frequently - It PROLONGS QT but RARELY causes TdP (due to homogeneous prolongation)
Forgetting that sotalol has BOTH Class II AND Class III properties - It is a beta-blocker with K+ channel blocking activity
Saying lidocaine is effective for atrial arrhythmias - It is NOT; it only works for ventricular arrhythmias
Forgetting the CAST trial implications - If a question involves post-MI patient with arrhythmias, Class IC is wrong
Treating WPW + AF with verapamil - DANGEROUS. This is a classic killer question.
Confusing procainamide and quinidine drug interactions with digoxin - BOTH increase digoxin levels. Quinidine AND amiodarone both increase digoxin. Learn all three.
Saying procainamide lupus is the same as SLE - Drug-induced lupus is ANA-positive, anti-histone antibody positive, but DOES NOT cause nephritis or CNS disease (unlike true SLE). It REVERSES on stopping the drug.
Forgetting that mexiletine is the oral form of lidocaine's class (IB) - and that GI side effects are its main toxicity (not CNS)
Using Class IA or Class III drugs to treat Torsades de Pointes - These prolong QT and will WORSEN TdP. Magnesium is the answer.
Forgetting that dronedarone is contraindicated in permanent AF with HF - The PALLAS trial showed increased mortality in this population.

SECTION 8: SPECIAL TOPICS

The CAST Trial - Why It Changed Everything (1989)

Before 1989, the thinking was: "Ventricular arrhythmias after MI → suppress them with antiarrhythmics → prevent sudden death."

The CAST trial tested flecainide and encainide in post-MI patients with asymptomatic ventricular ectopy.

Result: Sudden death was DOUBLED in the flecainide/encainide group compared to placebo.

Lesson: Suppressing a surrogate marker (ectopic beats) does not always improve outcomes. Antiarrhythmic drugs can be proarrhythmic. The drug that silences a rhythm problem on paper can create a deadlier one in the ischemic substrate.

This trial established that not all arrhythmias need treatment and that structural heart disease is a contraindication to Class IC drugs.

Drug-Induced QT Prolongation and Torsades de Pointes

This is an extremely important drug safety issue in clinical practice:

Common drugs that prolong QT (beyond antiarrhythmics):

Macrolide antibiotics: Azithromycin, erythromycin
Fluoroquinolones: Ciprofloxacin, moxifloxacin
Antifungals: Fluconazole
Antipsychotics: Haloperidol, chlorpromazine, ziprasidone
Tricyclic antidepressants
Antiemetics: Metoclopramide, droperidol
Antihistamines: Terfenadine, astemizole (withdrawn due to TdP risk)

Risk factors for drug-induced TdP:

Baseline QT prolongation
Female sex (women have slightly longer QT at baseline)
Hypokalemia and hypomagnesemia
Bradycardia (slower rate = longer QT)
Structural heart disease
High drug concentrations (overdose, renal failure, CYP inhibitor co-administration)

Prevention:

Check baseline QTc before starting
Correct electrolytes
Avoid combinations of multiple QT-prolonging drugs
Monitor ECG regularly

WPW Syndrome and Antiarrhythmics

WPW (Wolff-Parkinson-White) syndrome involves an accessory pathway (Bundle of Kent) that bypasses the AV node. This has critical implications for drug choice:

In WPW with SVT (without AF):

Adenosine or verapamil may be used
The re-entry circuit can go: AV node down → bundle of Kent back up (orthodromic)

In WPW with AF (pre-excited AF):

The accessory pathway conducts extremely rapidly (no decremental conduction like the AV node)
Drugs that BLOCK the AV node (verapamil, diltiazem, beta-blockers, digoxin, adenosine) will drive ALL impulses down the accessory pathway → extremely rapid ventricular rate → VF → death

The safe drugs in WPW+AF: Procainamide (IV), cardioversion

The dangerous drugs in WPW+AF: Verapamil, diltiazem, beta-blockers, digoxin, adenosine

SECTION 9: HIGH-YIELD REVISION SHEET

One-Page Rapid Review: Antiarrhythmics

Must-Know Classification

CLASS IA: Quinidine, Procainamide, Disopyramide
   → Na+ block (moderate) + K+ block → Wide QRS + Long QT
   → Quinidine: cinchonism, ↑digoxin levels
   → Procainamide: DRUG-INDUCED LUPUS (slow acetylators), NAPA metabolite
   → Disopyramide: urinary retention (anticholinergic), HF risk, useful in HOCM

CLASS IB: Lidocaine (IV), Mexiletine (oral)
   → Na+ block (fast kinetics) → preferential ischemic tissue → shorten APD
   → Lidocaine: CNS toxicity (nystagmus → seizures), IV only
   → Mexiletine: GI toxicity (nausea/vomiting)
   → ONLY for ventricular arrhythmias; NOT atrial

CLASS IC: Flecainide, Propafenone
   → Na+ block (slow, potent) → markedly wide QRS
   → CONTRAINDICATED in structural heart disease (CAST trial - ↑mortality in MI)
   → Propafenone: also weak beta-block → bronchospasm
   → Safe only in structurally NORMAL hearts (AF/flutter)

CLASS II: Beta-blockers (Metoprolol, Atenolol, Esmolol, Propranolol)
   → Slow Phase 4 (SA node) → bradycardia
   → Prolong PR (AV node block)
   → POST-MI: drug of choice; SVT; rate control in AF
   → Esmolol: half-life 9 min (IV, perioperative)

CLASS III: K+ channel blockers
   → Prolong Phase 3 → long QT → anti-re-entry
   → Amiodarone: BEST antiarrhythmic; Class I+II+III+IV
      Toxicity: THYROID, PULMONARY, LIVER, SKIN (blue-gray + photosensitivity), CORNEAL DEPOSITS
      Half-life: 40-55 DAYS; ↑warfarin; ↑digoxin
   → Sotalol: beta-block + K+ block; TdP risk; AVOID in asthma
   → Dofetilide: pure K+ block; safe in HF; high TdP; renal dosing
   → Ibutilide: IV; acute AF/flutter cardioversion; HIGH TdP risk (4%)
   → Dronedarone: no iodine, no thyroid/lung toxicity; CONTRAINDICATED in permanent AF + HF

CLASS IV: Verapamil, Diltiazem (non-DHP CCBs)
   → Block Ca2+ channels in SA/AV nodes
   → Rate control in AF; terminate SVT
   → CONTRAINDICATED in WPW+AF, systolic HF (verapamil especially), + beta-blockers IV
   → Verapamil: constipation, gingival hyperplasia

Must-Know Toxicities

Drug	Unique Toxicity
Quinidine	Cinchonism, increases digoxin levels
Procainamide	Drug-induced lupus (SLE), anti-histone Abs
Disopyramide	Anticholinergic (urinary retention, dry mouth)
Lidocaine	CNS toxicity: nystagmus, seizures (NOT cardiac)
Flecainide/IC	Proarrhythmia; increased mortality post-MI (CAST)
Amiodarone	Thyroid + pulmonary + liver + corneal + blue-gray skin
Sotalol	TdP, bronchospasm
Ibutilide	TdP (4% incidence)
Digoxin	Yellow vision, PAT with block, toxic on hypokalemia
Adenosine	Flushing, chest tightness, transient AV block, bronchospasm

Must-Know Drug Interactions

Offending Drug	Object Drug	Effect	Action
Quinidine	Digoxin	↑ digoxin 2x	Halve digoxin dose
Amiodarone	Warfarin	↑ anticoagulation (↑ bleeding)	Reduce warfarin ~30-50%
Amiodarone	Digoxin	↑ digoxin levels	Halve digoxin dose
Verapamil	Digoxin	↑ digoxin levels	Monitor closely
Verapamil	Beta-blockers (IV)	Severe bradycardia, asystole	AVOID combination IV
CYP2D6 inhibitors	Mexiletine	↑ mexiletine toxicity	Caution

Exam Emergency Facts

Adenosine → Drug of choice for acute SVT (rapid IV bolus, short half-life < 10 sec)
Magnesium sulfate → Drug of choice for Torsades de Pointes
Procainamide → Drug-induced lupus (slow acetylators more prone)
Lidocaine → IV only; CNS toxicity (seizures); ONLY for ventricular arrhythmias
Amiodarone → Most effective; all 4 classes; multi-organ toxicity; half-life 40-55 days
Flecainide/Class IC → CONTRAINDICATED post-MI (CAST trial)
Verapamil → CONTRAINDICATED in WPW+AF (causes VF) and in systolic HF
Digoxin → Toxic in hypokalemia; antidote = Digibind (Fab fragments)
Sotalol → Class II + III; AVOID in asthma (beta-blockade)
Post-MI arrhythmia prevention → Beta-blockers (NOT Class IC)

SECTION 10: SELF-ASSESSMENT

10 Short-Answer Questions with Explanations

Question 1: A 40-year-old woman presents with palpitations. ECG shows narrow complex tachycardia at 185 bpm. Vagal maneuvers fail. What is the drug of choice for acute termination, and what is the mechanism?

Answer: Adenosine (6 mg rapid IV bolus, followed by 12 mg if needed). Mechanism: Adenosine binds A1 receptors on AV nodal cells, activating the acetylcholine-sensitive K+ channel (IKAch). This hyperpolarizes the AV nodal cell, causing transient complete AV block (~10-30 seconds). Since AVNRT (the most common SVT) requires AV nodal conduction for its re-entry circuit, blocking the AV node terminates the circuit. Half-life < 10 seconds means effects are brief and self-limiting.

Question 2: A patient is being started on amiodarone for ventricular tachycardia. He is also taking warfarin (INR 2.5). What monitoring is required and why?

Answer: Amiodarone inhibits CYP2C9, which is responsible for metabolizing warfarin. This raises warfarin blood levels significantly, increasing the anticoagulant effect and bleeding risk. The INR will rise above therapeutic range. Warfarin dose should be empirically reduced by 30-50% when amiodarone is started, and INR should be monitored closely every 1-2 weeks until stable. Additionally, since amiodarone has a half-life of 40-55 days, its enzyme-inhibitory effect persists for weeks to months even after stopping amiodarone - warfarin dose adjustment must be maintained during this period.

Question 3: Why is lidocaine NOT given orally as an antiarrhythmic drug?

Answer: Lidocaine undergoes extensive first-pass metabolism in the liver (hepatic extraction ratio approximately 70%). When given orally, most of the drug is metabolized before it reaches the systemic circulation, resulting in negligible plasma levels and no antiarrhythmic effect. Oral administration is therefore therapeutically useless. For oral therapy of ventricular arrhythmias in the same class, mexiletine (a structurally similar Class IB drug) is used instead, as it is resistant to first-pass metabolism.

Question 4: A 50-year-old man with a previous myocardial infarction has atrial fibrillation. Why is flecainide contraindicated? What drugs would you use instead?

Answer: Flecainide (Class IC) is contraindicated because post-MI patients have structural heart disease with ischemic scar tissue. The CAST trial (1989) demonstrated that flecainide and other Class IC drugs increased the rate of sudden cardiac death in post-MI patients with ventricular ectopy. The mechanism is proarrhythmia: marked Na+ channel blockade slows conduction in ischemic tissue so severely that new re-entry circuits are created, leading to fatal ventricular arrhythmias.

Safer alternatives: For AF rate control in post-MI: beta-blockers or digoxin. For rhythm control (sinus rhythm maintenance): Amiodarone is the drug of choice in structural heart disease. Dofetilide is an alternative, particularly in heart failure.

Question 5: What is Torsades de Pointes? How do you treat it?

Answer: Torsades de Pointes (TdP) is a form of polymorphic ventricular tachycardia (VT) associated with a prolonged QT interval. On ECG, the QRS complexes appear to "twist" around the isoelectric baseline - the amplitude gradually increases then decreases over 5-20 beats, giving the characteristic morphology. It often self-terminates but can degenerate into ventricular fibrillation.

Mechanism: QT prolongation (from drugs, electrolyte disturbances, or congenital long QT syndrome) creates a long vulnerable period during repolarization. Early afterdepolarizations (EADs) occur during the prolonged Phase 2-3 and can trigger a new action potential, initiating TdP.

Treatment:

IV Magnesium Sulfate (2 g bolus) - first-line, even if Mg2+ is normal. Stabilizes the myocardium and suppresses EADs.
Remove causative drug (stop offending antiarrhythmic, antibiotic, etc.)
Correct electrolytes (especially K+; keep K+ > 4.5 mEq/L)
If persistent: Temporary pacing or isoproterenol to increase heart rate (faster rate shortens QT interval, preventing TdP)
If unstable: Immediate defibrillation

DO NOT use: Class IA or Class III drugs (they further prolong QT).

Question 6: What is the unique adverse effect of procainamide? What antibody is associated with it?

Answer: Procainamide causes drug-induced lupus erythematosus (DILE). With chronic use, 25-30% of patients develop this syndrome. Features include arthralgia, arthritis, pleuritis, pericarditis, and skin rash - mimicking systemic lupus erythematosus.

Antibodies: Nearly all patients on long-term procainamide develop positive ANA (antinuclear antibodies). The antibody most specifically associated is anti-histone antibody - this is characteristic of drug-induced lupus and helps distinguish it from idiopathic SLE.

Important distinctions from true SLE:

Drug-induced lupus does NOT typically cause glomerulonephritis (renal disease)
Drug-induced lupus does NOT cause CNS manifestations
It is reversible on stopping the drug
Anti-dsDNA antibodies (characteristic of true SLE) are usually NEGATIVE in drug-induced lupus

Who is most at risk? Slow acetylators - they metabolize procainamide more slowly, resulting in higher drug accumulation and greater lupus risk.

Question 7: A patient with WPW syndrome develops atrial fibrillation. Which drugs are DANGEROUS? Which is safe?

Answer: WPW syndrome involves an accessory pathway (Bundle of Kent) that bypasses the AV node. In AF, multiple atrial impulses (400-600/min) are generated. Normally, the AV node acts as a gatekeeper, allowing only 100-180/min through to the ventricles.

DANGEROUS drugs:

Verapamil and Diltiazem - block AV node but can paradoxically enhance conduction through the accessory pathway, allowing extremely rapid ventricular rates (300+ bpm) → VF → death
Beta-blockers - same principle (block AV node, may increase accessory pathway conduction)
Digoxin - shortens accessory pathway refractory period, accelerating conduction through it
Adenosine - similar concern (though it is sometimes used diagnostically with caution)

Safe and preferred treatment:

IV Procainamide - blocks the accessory pathway conduction AND AV node conduction (drug of choice for WPW+AF in hemodynamically stable patient)
Synchronized DC cardioversion - if hemodynamically unstable

Question 8: Compare the adverse effects of verapamil and diltiazem.

Answer:

Feature	Verapamil	Diltiazem
Negative inotropy	MORE prominent	Less
Constipation	PROMINENT (characteristic)	Less common
Gingival hyperplasia	Present (rare)	Not significant
AV block	Both can cause	Both can cause
Hypotension	Both	Both
Peripheral edema	Less	More prominent
Gynecomastia	Reported (rare)	Not characteristic
Heart failure risk	Higher (avoid in systolic HF)	Slightly lower risk

Common to both: Bradycardia, AV block, hypotension, dizziness. Both are contraindicated in WPW+AF, decompensated systolic heart failure, severe bradycardia/heart block, and should not be combined with IV beta-blockers.

Question 9: A patient develops visual changes and yellow-green colored vision. They have bradycardia and ECG shows paroxysmal atrial tachycardia with AV block. What drug is responsible and how do you treat?

Answer: This is classic digoxin toxicity.

Diagnosis:

Xanthopsia (yellow-green vision) - the famous visual side effect, described by some painters (notably Van Gogh is theorized to have been on digitalis)
Nausea/vomiting - usually the first symptoms
PAT (paroxysmal atrial tachycardia) with AV block - the most pathognomonic ECG finding of digoxin toxicity (enhanced automaticity of atrial tissue + increased AV block)
Bradycardia - vagotonic effect + Na+/K+-ATPase inhibition in SA node

Treatment:

STOP digoxin immediately
Correct hypokalemia (most common precipitant) - give IV KCl carefully
Correct hypomagnesemia
For bradycardia/AV block: Atropine (0.5 mg IV); temporary pacing if unresponsive
For ventricular arrhythmias: Lidocaine or phenytoin (NOT quinidine - it increases digoxin levels further!)
For severe/life-threatening toxicity: Digoxin-specific Fab antibody fragments (Digibind/DigiFab) - the specific antidote. Each vial binds ~0.5 mg digoxin. Dose calculated based on ingested amount or serum digoxin level.

Question 10: What is the half-life of amiodarone? Why is it clinically significant?

Answer: The half-life of amiodarone is 40-55 days (range 15-142 days). This is the longest half-life of any commonly used drug, and it has several major clinical implications:

Loading dose required: Because the drug distributes so extensively into fat, liver, lungs, and other tissues (enormous volume of distribution ~60 L/kg), it takes weeks to reach effective plasma and tissue levels. A loading regimen is used to rapidly achieve therapeutic levels.
Slow onset of action: Even with a loading dose, full antiarrhythmic effect may take days to weeks.
Drug interactions persist long after stopping: Amiodarone's inhibition of CYP2C9 (affecting warfarin) and CYP3A4 continues for months after the drug is discontinued. This means the drug may continue to raise warfarin levels for months after stopping.
Adverse effects persist: If a patient develops pulmonary toxicity or thyroid dysfunction, the drug continues to accumulate (and remains in tissues) for months even after stopping. Toxicity may worsen briefly after discontinuation.
Cannot quickly adjust: Unlike drugs with short half-lives (e.g., esmolol: 9 minutes), amiodarone cannot be titrated rapidly. Once started, it takes months to fully wash out.
Monitoring must continue months after stopping: Because the drug persists, organ monitoring (thyroid, liver, lungs) must continue well beyond drug discontinuation.

This comprehensive learning note was compiled from: Lippincott Illustrated Reviews: Pharmacology; Goodman & Gilman's The Pharmacological Basis of Therapeutics; Harrison's Principles of Internal Medicine 22e (2025); Katzung's Basic and Clinical Pharmacology 16e; Braunwald's Heart Disease; Goldman-Cecil Medicine; The Washington Manual of Medical Therapeutics.

End of Antiarrhythmics Complete Learning Note

This is a shared conversation. Sign in to Orris to start your own chat.